This study utilizes patient‐derived osteosarcoma organoids and CRISPR screening to identify ERCC6 and HNRNPM as key mediators of cisplatin resistance via the PI3K/AKT pathway and BAX alternative splicing. Here, HNRNPM is linked to osteosarcoma.